Terms: = Breast cancer AND SRC, c-SRC, 6714, ENSG00000197122, P12931, ASV, p60-Src, SRC1, c-src AND Clinical Outcome
22 results:
1. Mutant TP53 interacts with BCAR1 to contribute to cancer cell invasion.
Guo AK; Itahana Y; Seshachalam VP; Chow HY; Ghosh S; Itahana K
Br J Cancer; 2021 Jan; 124(1):299-312. PubMed ID: 33144694
[TBL] [Abstract] [Full Text] [Related]
2. Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance.
Li L; Lin L; Veeraraghavan J; Hu Y; Wang X; Lee S; Tan Y; Schiff R; Wang XS
Breast Cancer Res; 2020 Aug; 22(1):84. PubMed ID: 32771039
[TBL] [Abstract] [Full Text] [Related]
3. Estrogen-regulated feedback loop limits the efficacy of estrogen receptor-targeted breast cancer therapy.
Xiao T; Li W; Wang X; Xu H; Yang J; Wu Q; Huang Y; Geradts J; Jiang P; Fei T; Chi D; Zang C; Liao Q; Rennhack J; Andrechek E; Li N; Detre S; Dowsett M; Jeselsohn RM; Liu XS; Brown M
Proc Natl Acad Sci U S A; 2018 Jul; 115(31):7869-7878. PubMed ID: 29987050
[TBL] [Abstract] [Full Text] [Related]
4. Epigenome-wide src-1-Mediated Gene Silencing Represses Cellular Differentiation in Advanced breast cancer.
Ward E; Varešlija D; Charmsaz S; Fagan A; Browne AL; Cosgrove N; Cocchiglia S; Purcell SP; Hudson L; Das S; O'Connor D; O'Halloran PJ; Sims AH; Hill AD; Young LS
Clin Cancer Res; 2018 Aug; 24(15):3692-3703. PubMed ID: 29567811
[No Abstract] [Full Text] [Related]
5. Chemotherapy-Induced Ca
Lu H; Chen I; Shimoda LA; Park Y; Zhang C; Tran L; Zhang H; Semenza GL
Cell Rep; 2017 Feb; 18(8):1946-1957. PubMed ID: 28228260
[TBL] [Abstract] [Full Text] [Related]
6. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.
Bayraktar R; Pichler M; Kanlikilicer P; Ivan C; Bayraktar E; Kahraman N; Aslan B; Oguztuzun S; Ulasli M; Arslan A; Calin G; Lopez-Berestein G; Ozpolat B
Oncotarget; 2017 Feb; 8(7):11641-11658. PubMed ID: 28036267
[TBL] [Abstract] [Full Text] [Related]
7. Comprehensive functional analysis of the tousled-like kinase 2 frequently amplified in aggressive luminal breast cancers.
Kim JA; Tan Y; Wang X; Cao X; Veeraraghavan J; Liang Y; Edwards DP; Huang S; Pan X; Li K; Schiff R; Wang XS
Nat Commun; 2016 Oct; 7():12991. PubMed ID: 27694828
[TBL] [Abstract] [Full Text] [Related]
8. Proteomic modulation in breast tumors after metformin exposure: results from a "window of opportunity" trial.
Kalinsky K; Zheng T; Hibshoosh H; Du X; Mundi P; Yang J; Refice S; Feldman SM; Taback B; Connolly E; Crew KD; Maurer MA; Hershman DL
Clin Transl Oncol; 2017 Feb; 19(2):180-188. PubMed ID: 27305912
[TBL] [Abstract] [Full Text] [Related]
9. A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing breast cancer.
Menyhárt O; Santarpia L; Győrffy B
Curr Cancer Drug Targets; 2015; 15(8):665-83. PubMed ID: 26452383
[TBL] [Abstract] [Full Text] [Related]
10. PKA signaling drives mammary tumorigenesis through src.
Beristain AG; Molyneux SD; Joshi PA; Pomroy NC; Di Grappa MA; Chang MC; Kirschner LS; Privé GG; Pujana MA; Khokha R
Oncogene; 2015 Feb; 34(9):1160-73. PubMed ID: 24662820
[TBL] [Abstract] [Full Text] [Related]
11. src and CXCR4 are involved in the invasiveness of breast cancer cells with acquired resistance to lapatinib.
De Luca A; D'Alessio A; Gallo M; Maiello MR; Bode AM; Normanno N
Cell Cycle; 2014; 13(1):148-56. PubMed ID: 24200972
[TBL] [Abstract] [Full Text] [Related]
12. Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer.
Weiner M; Skoog L; Fornander T; Nordenskjöld B; Sgroi DC; Stål O
Ann Oncol; 2013 Aug; 24(8):1994-9. PubMed ID: 23670096
[TBL] [Abstract] [Full Text] [Related]
13. Cytoplasmic localization of alteration/deficiency in activation 3 (ADA3) predicts poor clinical outcome in breast cancer patients.
Mirza S; Rakha EA; Alshareeda A; Mohibi S; Zhao X; Katafiasz BJ; Wang J; Gurumurthy CB; Bele A; Ellis IO; Green AR; Band H; Band V
Breast Cancer Res Treat; 2013 Feb; 137(3):721-31. PubMed ID: 23288344
[TBL] [Abstract] [Full Text] [Related]
14. Identification of novel functional and spatial associations between sphingosine kinase 1, sphingosine 1-phosphate receptors and other signaling proteins that affect prognostic outcome in estrogen receptor-positive breast cancer.
Ohotski J; Edwards J; Elsberger B; Watson C; Orange C; Mallon E; Pyne S; Pyne NJ
Int J Cancer; 2013 Feb; 132(3):605-16. PubMed ID: 22733311
[TBL] [Abstract] [Full Text] [Related]
15. Shorter disease-specific survival of ER-positive breast cancer patients with high cytoplasmic src kinase expression after tamoxifen treatment.
Elsberger B; Paravasthu DM; Tovey SM; Edwards J
J Cancer Res Clin Oncol; 2012 Feb; 138(2):327-32. PubMed ID: 22134837
[TBL] [Abstract] [Full Text] [Related]
16. Oestrogen receptor-co-factor-chromatin specificity in the transcriptional regulation of breast cancer.
Zwart W; Theodorou V; Kok M; Canisius S; Linn S; Carroll JS
EMBO J; 2011 Oct; 30(23):4764-76. PubMed ID: 22002538
[TBL] [Abstract] [Full Text] [Related]
17. Is there an association with phosphorylation and dephosphorylation of src kinase at tyrosine 530 and breast cancer patient disease-specific survival.
Elsberger B; Tan BA; Mallon EA; Brunton VG; Edwards J
Br J Cancer; 2010 Dec; 103(12):1831-4. PubMed ID: 21063412
[TBL] [Abstract] [Full Text] [Related]
18. breast cancer patients' clinical outcome measures are associated with src kinase family member expression.
Elsberger B; Fullerton R; Zino S; Jordan F; Mitchell TJ; Brunton VG; Mallon EA; Shiels PG; Edwards J
Br J Cancer; 2010 Sep; 103(6):899-909. PubMed ID: 20717116
[TBL] [Abstract] [Full Text] [Related]
19. p130Cas is an essential transducer element in ErbB2 transformation.
Cabodi S; Tinnirello A; Bisaro B; Tornillo G; del Pilar Camacho-Leal M; Forni G; Cojoca R; Iezzi M; Amici A; Montani M; Eva A; Di Stefano P; Muthuswamy SK; Tarone G; Turco E; Defilippi P
FASEB J; 2010 Oct; 24(10):3796-808. PubMed ID: 20505116
[TBL] [Abstract] [Full Text] [Related]
20. Effect of low-dose tamoxifen on steroid receptor coactivator 3/amplified in breast cancer 1 in normal and malignant human breast tissue.
Haugan Moi LL; Hauglid Flågeng M; Gandini S; Guerrieri-Gonzaga A; Bonanni B; Lazzeroni M; Gjerde J; Lien EA; DeCensi A; Mellgren G
Clin Cancer Res; 2010 Apr; 16(7):2176-86. PubMed ID: 20332317
[TBL] [Abstract] [Full Text] [Related]
[Next]
